FDA Approves Lilly's Axiron

Zacks.com submits:

Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence.

Eli Lilly acquired exclusive worldwide rights to commercialize Axiron earlier this year. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. With Axiron having gained FDA approval, Acrux now stands to receive a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the produ

By admin posted about 1 year ago

Filings 0 | Comments 0 | Views 182